"Amyloid immunotherapy has consistently shown an increase in brain volume loss – leading to concerns in the media and medical ...

A study conducted bà Cattolica in Rome and the Fondazione Policlinico Universitario Agostino Gemelli IRCCS has uncovered a ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

Alzheimer’s disease remains one of the most pressing challenges in modern medicine, ranking as a leading cause of death ...

While we have made progress with FDA approval of two treatments that can slow cognitive decline in early-stage Alzheimer’s ...

A potential new treatment for Alzheimer’s disease may come in the form of a nasal spray. Researchers in Italy have discovered ...

Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques ...

People who are obese and harbor deep belly fat are at higher risk for developing Alzheimer's disease-specific proteins in the ...

"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...

Their results identify crucial shared pathways, confirming that the Alzheimer's in a dish model can be used to assess new drugs accurately and rapidly as well as point the way to drug discovery.

Visceral fat has been linked to early Alzheimer’s disease pathology, according to a study of midlife individuals. Researchers ...

Scientists have created a game-changing 'Alzheimer's in a dish' model that allows for faster and more accurate testing of ...